Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 2/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 3/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12305127 | 0.90 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL17614667 | 0.88 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL13171247 | 0.87 | MEN1 (0.59) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL16089528 | 0.84 | MGLL (0.54) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL17694233 | 0.82 | TP53 (0.44) | ALDH1A1SMN1; SMN2POLBDRD2MGLL | |
| Trifluoroacetic Acid SCHEMBL22973513 | 0.78 | DRD2 (0.47) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL16096215 | 0.77 | PTGS1 (0.48) | ALDH1A1SMN1; SMN2DRD2DRD3MGLL | |
| SCHEMBL20246935 | 0.76 | MGLL (0.46) | ALDH1A1SMN1; SMN2DRD2DRD3MGLL | |
| SCHEMBL12697308 | 0.76 | MTNR1A (0.56) | ALDH1A1SMN1; SMN2MGLLFAAHHSP90AA1 | |
| SCHEMBL9737672 | 0.76 | MGLL (0.46) | ALDH1A1SMN1; SMN2DRD2DRD3MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023018960-A1 | IMPROVED METHODS FOR PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| US-20170088668-A1 | N-MALEIMIDYL POLYMER DERIVATIVES | NEKTAR THERAPEUTICS | 2017-03-30 | — | — | US | disclosed |
| US-9169350-B2 | N-maleimidyl polymer derivatives | NEKTAR THERAPEUTICS (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150209440-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150166725-A1 | N-Maleimidyl Polymer Derivatives | NEKTAR THERAPEUTICS (US) | 2015-06-18 | — | — | US | disclosed |
| WO-2015057847-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | CERULEAN PHARMA INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| US-8992902-B2 | N-maleimidyl polymer derivatives | NEKTAR THERAPEUTICS (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140296322-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140256957-A1 | N-Maleimidyl Polymer Derivatives | NEKTAR THERAPEUTICS (US) | 2014-09-11 | — | — | US | disclosed |
| US-8765111-B2 | N-maleimidyl polymer derivatives | NEKTAR THERAPEUTICS (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140037573-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | CERULEAN PHARMA INC (US) | 2014-02-06 | — | — | US | disclosed |
| WO-2013126564-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | CERULEAN PHARMA INC. (US) | 2013-08-29 | — | — | WO | disclosed |
| US-8454946-B2 | N-maleimidyl polymer derivatives | NEKTAR THERAPEUTICS (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120225129-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | CERULEAN PHARMA INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20090246211-A1 | Molecular constructs suitable for targeted conjugates | TAPESTRY PHARMACEUTICALS, INC. | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088668-A1 | N-MALEIMIDYL POLYMER DERIVATIVES | NGLY1, PIN1, NMT2 | ALDH1A1 4566/4885SMN1; SMN2 1918/4885POLB 2901/4885 |
| US-20140296322-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CD44, DIS3, POLN | ALDH1A1 2920/4885SMN1; SMN2 347/4885POLB 79/4885 |
| US-20140037573-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | SYNCRIP, EXOSC5, EXOSC9 | ALDH1A1 3222/4885SMN1; SMN2 558/4885POLB 127/4885 |
| US-20150209440-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CD44, DIS3, POLN | ALDH1A1 2920/4885SMN1; SMN2 347/4885POLB 79/4885 |
| US-20090246211-A1 | Molecular constructs suitable for targeted conjugates | MRPL21, QSOX1, MLX | ALDH1A1 820/4885SMN1; SMN2 3913/4885POLB 3551/4885 |
| US-20120225129-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | SYNCRIP, EXOSC5, EXOSC9 | ALDH1A1 3222/4885SMN1; SMN2 558/4885POLB 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.